On April 23, the third meeting of the CAPN12-IO project consortium members took place at the facilities of the Fundación para la Investigación Biomédica del Hospital Universitario Doce de Octubre in Madrid.

Landsteiner Genmed has announced that it has obtained 2,055M € of non-dilutive funding from Next Generation EU Funds to study the anticancer effects of new molecules with immunomodulatory properties.

NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in two experimental models of heart failure.